Bristol-myers Squibb Compnay

Viiv Healthcare UK (no.5) Limited

Viiv Healthcare UK Limited

Barry L Johnson

David J Carini

John F Kadow

Tao Wang

Zhongxing Zhang

Nicholas A Meanwell

Zhiwei Yin

Paul Michael Scola

Lawrence G Hamann

B Narasimhulu Naidu

Alicia Regueiro-Ren

Yasutsugu Ueda

Manoj Patel

Jacob Swidorski

Michael A Walker

Stanley V D'Andrea

Kevin M Peese

Margaret E Sorenson

Zheng Liu

Zhizhen Barbara Zheng

Andrew Charles Good

Edward H Ruediger

John A Bender

Jeffrey Allen Campbell

Daniel H Deon

Kenneth M Boy

Clint A James

Timothy P Connolly

Michael S Bowsher

Chen Li

Fiona McPhee

Rongti Li

Nicolas A Meanwell

Yasutsuga Ueda

Alicia Regueiro-ren

Compounds of Formula I, including pharmaceutically acceptable salts thereof: I useful as HIV attachment inhibitors. 

2-keto amide derivatives as HIV attachment inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts thereof: formula (I): wherein A is selected from the group consisting of: formula (II) and wherein Z is selected from the group consisting of: formula (III): and. are useful as HIV attachment inhibitors. 

Piperidine amide derivatives as HIV attachment inhibitors

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV. 

HIV integrase inhibitors

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Inhibitors of human immunodeficiency virus replication

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives of Formula I: that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

Diketo substituted pyrrolo[2,3-C]pyridines

Diketo substituted pyrrolo[2,3-c] pyridines

Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Hepatitis C virus inhibitors

Macrocyclic isoquinoline peptides are disclosed having the general formula: A compound of formula I:  wherein Rto R, Q and W are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus

Growing community of inventors

Wallingford, CT, United States of America

Barry L Johnson